{"name":"Aerie Pharmaceuticals","slug":"aerie-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"Aerie Pharmaceuticals was an American clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates were once-daily therapies for lowering intraocular pressure with mechanisms to treat patients with glaucoma or ocular hypertension.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":194134000,"revenueGrowth":133.5,"grossMargin":0,"rdSpend":75837000,"netIncome":-74810000,"cash":431391000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Latanoprost ophthalmic solution 0.005%","genericName":"Latanoprost ophthalmic solution 0.005%","slug":"latanoprost-ophthalmic-solution-0-005","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Latanoprost ophthalmic solution 0.005%","genericName":"Latanoprost ophthalmic solution 0.005%","slug":"latanoprost-ophthalmic-solution-0-005","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxObTMydGNtQlFXLUpDMGxFSmNoUW8zdVhYcW85aVhWU3lrb2Flem1KNEtHWmVnTDJ4ZzA2dV9xUnlVZVpIOVRVUlhKa3ZqbkVhUFpCY2s5Q2xqNTU0dmJxZEdWMjRrV1FBY084eGMySEdJSjJxb28zWVRYZnliSjZIZk5lU1FEdlBEdkUyUmx0NC1WcjRneElLVlBSVng3d2FOMGZLcVhmM2tTUQ?oc=5","date":"2025-05-29","type":"regulatory","source":"Fierce Pharma","summary":"Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease - Fierce Pharma","headline":"Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNdjBoSmdWaV8zaHJCd21ydDNUcDZEblptdWF5UHRyZjQzaW1DTVNfbXVxSW9sc0psdUNvMWwxQnFaRTRLdm4tY3IwUTNyNUtYdWhaSlYzQUx3TnRNejRMSlpxNFRBSU9NNzFIWW5UNWM4emR0RVVleTlMNTF3Wm5mTg?oc=5","date":"2024-06-15","type":"pipeline","source":"Medical Device and Diagnostic industry","summary":"Alcon Indulges in its Pharma Side for New M&A - Medical Device and Diagnostic industry","headline":"Alcon Indulges in its Pharma Side for New M&A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPajJSX1p6TTJueDJVNjhYN3VSNkRIWWlHaDdCV3hzOW5yYk1rX3dJeDJVT05sYkRFa0dNQnRTeW5FakxucE5tQUhkbE1CVUtBU1c0RU5jOGZBSEJOQUg3SXVkcXNyUU1NYXZwMDhZbllMSDRIQ2xocmFRS0FVVFV5dXBSdWM3Z0V3czhuaG9DMWNOS2NLb3BNbzB1QnMzeDFqSVJmX2dPRWp2R1I3SUE?oc=5","date":"2024-01-10","type":"trial","source":"Fierce Biotech","summary":"Alcon’s dry eye ambitions take off as $770M Aerie takeover delivers phase 3 wins - Fierce Biotech","headline":"Alcon’s dry eye ambitions take off as $770M Aerie takeover delivers phase 3 wins","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQMTVOem16VTAwRG1pOUZFeVBtZXpNVW1KcThuYVdLZDN5clJnTHpKaGhaWVpOa2cyNVNqUFFkYzZWM3M4UFJva2lKV3VMVnVITHRjdElIVmdTTWQzUFowaTBFNF9Hcjl0Z0RyMEhpakV6ZTFBOFVTaTBoV2pselE3emsxek1IdEROdXVCTWYzaHZXVElkVUttc0JsX2ZVZjBzX0lKcWhtUHk5YW9UenZsWW1HZm5GMzE2WERvcFAwN1g?oc=5","date":"2022-11-03","type":"earnings","source":"Business Wire","summary":"Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results - Business Wire","headline":"Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE5zdVlidm9ieVNwQlV5R1hzaU13dTVtNWJYMlNGakVWWUV6S3AxZ3EyR0VIazJSQVhhZ0UtMkJfT2JXTFNpV1hSN1hVOEx2R3BDenp3bWlWYjJHcThhR1hUM254REtSSFZqZVhtaVBjY3NyZ9IBckFVX3lxTE9xWG0wV09oY29SRXM2LXEtbEgxV21KRHRJLVRCM0VlTEU3Wkp0bV8zeUI1M1ZhdjhINlRhcUZ1MVY3Ujk3S2RWSWhpQ1FvNnU1ODVqNmF0cS03bmNGZy04NzBSbHJMaXp4ZmJOS2o4Z3M3dw?oc=5","date":"2022-08-26","type":"deal","source":"Raleigh News & Observer","summary":"Durham pharma company acquired by international eye-care powerhouse for $770 million - Raleigh News & Observer","headline":"Durham pharma company acquired by international eye-care powerhouse for $770 million - Raleigh News & Observer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQUUpoeTZ3MzZLMXc0aHZVLWVHYS10dkpPdzJzblhubVBicUVRVGJZRHFHcXF6VHhrbHNWWWlLRG5GWDgtdDJwZnlPTk1NMVEwYm0xMDh2Tmg4X096enlBVlRFcnZGal9rWVdzYXhOM0NJWUpXZ3FCd1RVMUFTeG5acmxkYy0?oc=5","date":"2022-08-23","type":"deal","source":"Ophthalmology Times","summary":"Alcon to acquire Aerie Pharmaceuticals - Ophthalmology Times","headline":"Alcon to acquire Aerie Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNYV9lcm1jeGo0bkJfLVFPcHliUTk2MkNXM2JpcUF4YVMwb3U1SEFRRzlQaWE2M1JINDN5OVZHVmNCb2l4NURBTGpFMHBNSUsyYTIwTWU3bkZ1cFFxQUpObkdyNjc5a05JdEVmWlcxZk5OU3Z5SFVWQTZWMmNlZG9yOTlteWpRSlV4X3dfOA?oc=5","date":"2022-08-23","type":"pipeline","source":"BioPharma Dive","summary":"Aerie’s glaucoma drug journey ends in $770M sale to Alcon - BioPharma Dive","headline":"Aerie’s glaucoma drug journey ends in $770M sale to Alcon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQSUpnZGIxOFpneXRITzVwUEM3V3plN0xzdzFDcWZXVGhmYV9hbThWY3hFRUxXd0dFM0JhbG1EZVV1WEtIOFZSSk52RmU3cEdYdW5JUmNSN0pLTWJtaEp6alpRM3J2cnJhZWNOX0tERHJhR3E4YUIxVVZKSHVXOHZ0RkxXSThNS240Q0REaUFjYWhmZw?oc=5","date":"2022-08-23","type":"pipeline","source":"The Pharma Letter","summary":"Aerie Pharma rockets on news of takeover bid - The Pharma Letter","headline":"Aerie Pharma rockets on news of takeover bid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQUmNVbFktLTJnQldIM0lWUjV4V0RkeUZyOWI2YmhjazJSR1F4QnczbXViNGEzd3ViU1lPZlhleEhYTWVUc2pGYkxJUkRnTmNVWjBhMGFGX012WnFlR2FMUnd3U3ZfaUlwMXNvTVB3c19nd3ZSNWIwR2FBODltcHJKVWdybHJXb0h6SmI3MllOR3o2UQ?oc=5","date":"2022-08-23","type":"pipeline","source":"pharmaphorum","summary":"Alcon eyes $770m takeover of ophthalmology specialist Aerie - pharmaphorum","headline":"Alcon eyes $770m takeover of ophthalmology specialist Aerie","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPWE13QUVJMEtCZGNkX0traWw1Q0ZLOTFJSmo3MmhuNUpFaEdwdjhjQndSbENqZW1fT1JtN0lNRzJwYWFsNXBlZVZBZ0FSLTNNdmlvN3VlaWRDRGtJbG5WX2hWYVRsNlFzVWpPbWtYWmhreUxaRG5QaGlrQVB4WWhkUC1acld3NXhqWUs5Z0dobHFObXZLWlpNcGtmcUZ1LS0xemlWVU1MeXNLNlRmcjlVUFVXYUlwbUhxOVBIdEc2Ty1oS3ViVGl1eC10TGVkVHBlWmNmSG5R?oc=5","date":"2022-06-15","type":"pipeline","source":"PR Newswire","summary":"Visiox Pharma Appoints Industry Veteran Vicente Anido Jr., Ph.D., as a Strategic Advisor - PR Newswire","headline":"Visiox Pharma Appoints Industry Veteran Vicente Anido Jr., Ph.D., as a Strategic Advisor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQX3hORHEzaHM0ZXRLeExfSTN6N0NjalVycWtDcU80LVlOR0xmUjd6eXpYazhkb3A2Y1BlZ2tMQlFTSXlIRzlDVF92QkNZZnJGTGppQVJSZER6emdIZE4xOFgtQWdnM3dXcFoxNW9HOWpKeVpOTHZjWFVqU0JZRldPTUNhYjM4cGhRbGlOWS1wSnlYSzVPWG1pYjhPMHRHLWs0Yi1IQWFB?oc=5","date":"2022-01-26","type":"pipeline","source":"The Business Journals","summary":"Executive shakeup continues at Durham pharma in wake of CEO change - The Business Journals","headline":"Executive shakeup continues at Durham pharma in wake of CEO change","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOcEF1UzBsLW9IdXdpN3NVdHE2eUlWeTAtSmNyRmk0WkI0WW5uWXZxTm1pcko4OEwwbjZ0VUdoTHMyZGdJakVtcVdlVk9sVmhOOHZ1aWtkc3N2NGFleVRwemg3OHBoWWVBc1lyeUU2TldIdHdJNDhKQl8tU3BpaDJDUk10c3ltdUQ2dVRBMlJiNlFlWExfXzIyR1RSTk5pbEdYU1puLUlETkxTM3c?oc=5","date":"2021-12-16","type":"pipeline","source":"citybiz","summary":"Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer - citybiz","headline":"Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":194134000,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":194134000,"period":"2021-12-31"},{"value":83138000,"period":"2020-12-31"},{"value":83138000,"period":"2020-12-31"},{"value":24683000,"period":"2020-12-31"},{"value":20081000,"period":"2020-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":75837000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-74810000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":431391000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}